Arcturus Therapeutics Holdings Inc. (ARCT)
$15.82
$0.26
(1.67%)
As on 04-Sep-2026 17:45EDT
Market cap
$450 Mln
Revenue (TTM)
$24 Mln
P/E Ratio
--
P/B Ratio
2.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-25.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.3
-
Face value
--
-
Shares outstanding
28,423,069
10 Years Aggregate
CFO
$-257.39 Mln
EBITDA
$-396.19 Mln
Net Profit
$-433.90 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings (ARCT)
| 158.1 | 163.7 | 108.2 | -8.0 | -20.7 | -21.9 | -7.2 |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings (ARCT)
| -63.9 | -45.9 | 85.9 | -54.2 | -14.7 | 299.1 | 140.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings (ARCT)
|
15.8 | 449.7 | 23.8 | -93.3 | -257.3 | -48.4 | -- | 2.6 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Arcturus Therapeutics Holdings (ARCT)
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a... lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Read more
-
Founder, President, CEO & Director
Mr. Joseph E. Payne M.Sc.
-
Founder, President, CEO & Director
Mr. Joseph E. Payne M.Sc.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Arcturus Therapeutics Holdings (ARCT)
What is the current share price of Arcturus Therapeutics Holdings Inc (ARCT) Today?
The share price of Arcturus Therapeutics Holdings Inc (ARCT) is $15.82 (NASDAQ) as of 04-Sep-2026 17:45 EDT. Arcturus Therapeutics Holdings Inc (ARCT) has given a return of -20.71% in the last 3 years.
What is the current PB & PE ratio of Arcturus Therapeutics Holdings Inc (ARCT)?
Since, TTM earnings of Arcturus Therapeutics Holdings Inc (ARCT) is negative, P/E ratio is not available.
The P/B ratio of Arcturus Therapeutics Holdings Inc (ARCT) is 2.57 times as on 04-Sep-2026, a 52 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.55 |
0.78 |
2024 |
-5.66 |
1.90 |
2023 |
-28.24 |
3.01 |
2022 |
49.13 |
1.70 |
2021 |
-4.79 |
4.27 |
What is the 52 Week High and Low of Arcturus Therapeutics Holdings Inc (ARCT)?
The 52-week high and low of Arcturus Therapeutics Holdings Inc (ARCT) are Rs 24.17 and Rs 5.50 as of 08-Sep-2026.
What is the market cap of Arcturus Therapeutics Holdings Inc (ARCT)?
Arcturus Therapeutics Holdings Inc (ARCT) has a market capitalisation of $ 450 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Arcturus Therapeutics Holdings Inc (ARCT)?
Before investing in Arcturus Therapeutics Holdings Inc (ARCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.